ANDROGEL® Testosterone gel 1%
PrBIAXIN BID® Clarithromycin tablets
Pediatric PrBIAXIN® Clarithromycin suspension
PrCampral®
Clarus®
CLARUS® CLEARTM Program is a clinical education and awareness resource for patients and healthcare professionals that includes important safety information about PrCLARUS (isotretinoin capsules). To understand all risks associated with product use, please visit www.clarusclearprogram.ca for educational materials for physicians and patients.
For more information, visit Clarus in Product Catalogue.
PrCREON MINIMICROSPHERES® Lipase/amylase/protease
IMPORTANT: Changes in PrCreon Minimicrospheres® 25 (pancreatin) capsule shell. Click here to learn more.
PrDepakene® Valproic acid
PrDicetel® Pinaverium Bromide
PrDymista® Azelastine hydrochloride and fluticasone propionate
PrEpival® Divalproex sodium
PrGen-Clozapine
Gen-Clozapine Access Network (GenCAN) is a comprehensive support program for PrGen-Clozapine patients. GenCAN team includes full-time clinical nurses strategically located across Canada. The team provides exceptional evidence-based clinical monitoring and support, ensuring Health Canada’s product monograph requirements are met, and maximizing patient safety across Canada.
Gen-Clozapine Access Network
Phone: 1-866-501-3338
Fax: 1-800-497-9592
Website: www.gencan.ca
For more information, visit Gen-Clozapine in Product Catalogue.
PrGlatiramer Acetate Injection
For more information, visit Glatiramer Acetate Injection in Product Catalogue.
DInfluvac® Influenza vaccine
DINFLUVAC®TETRA Quadrivalent influenza vaccine, surface antigen, inactivated
PrIsoptin®SR Verapamil hydrochloride sustained-release tablets
NKadian® Morphine sulphate pentahydrate
PrLipidil EZ® Fenofibrate, NanoCrystal® formulation
PrLipidil Supra® Fenofibrate, microcoated formulation
PrLuvox® Fluvoxamine maleate
PrMavik® Trandolapril Capsules
Mylan-Dexrazoxane 250 mg powder for Injection (US-labelled)
Due to a shortage in Canada, Pfizer Canada ULC has informed Health Canada that a steady supply of its ZINECARD (Dexrazoxane for Injection) is not expected until January 31, 2021. Given the medical necessity of this product, Health Canada has expressed no objection to the temporary importation and distribution of US-labelled Mylan-Dexrazoxane for Injection.
PrMylan-Divalproex
To assist healthcare professionals and patients avoid exposure to Divalproex during pregnancy, please review the following educational materials as part of the Pregnancy Prevention Program.
Physician Annual Risk Acknowledgement Form
Patient Annual Risk Acknowledgement Form
For more information, visit Mylan-Divalproex, Product Catalogue
PrMylan-Fingolimod
VIATRIS ADVOCATE™ is a comprehensive support program for PrMylan-Fingolimod patients, including reimbursement navigation, financial assistance for eligible patients, and on-going support from MS-experienced nurses. For more information, please contact us at 1-888-223-0038 or viatris.advocate@sdmshn.ca.
To understand all risks associated with product use, please see below the educational materials for physicians and patients.
Risk Mitigation Plan – Patient Reminder Card
Risk Mitigation Plan – Patient-Parent-Caregiver Guide
Risk Mitigation Plan – Educational Material for HCPs
Mylan-Fingolimod Pregnancy Registry
Phone: 1-888-246-5830
Fax: 1-833-677-0484
E-mail: mylanfpr@innomar-strategies.com
Website: www.mylanfpr.ca
For more information, visit Mylan-Fingolimod in Product Catalogue.